FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

with carcinoma in situ (CIS) with or without papillary tumors, ImmunityBio announced in a news release. 1 The MHRA will now review the application for potential approval in the United Kingdom. “MHRA’s ...

with carcinoma in situ (CIS), with or without papillary tu CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...

9 Lesions with low malignant potential are common (such as low-risk ductal carcinoma in situ (DCIS), low-risk papillary thyroid cancer and low-grade prostate cancer), and with the advent and ...

Avelumab in combination with axitinib (Ave + Axi) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC): A systematic literature review (SLR) of real-world effectiveness and safety.

Comparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

[1] Bladder cancer is usually stratified into two broad categories: papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...